Absci Corporation’s stocks have been trading up by 28.2 percent following upbeat news on its AI-driven drug discovery progress.
Key Takeaways
- Leerink launched coverage with an Outperform rating and $12 target on Absci, spotlighting its AI-native drug discovery platform and ABS-201’s catalyst-rich 18‑month clinical window.
- Guggenheim lifted its Absci price target to $15 from $10, flagging ABS-201 as a potential $5B‑plus U.S. and $8B‑plus global sales opportunity if data deliver.
- BTIG started Absci at Buy with a $9 target and $2.2B peak sales view for ABS-201, calling it a potential GLP‑1‑like breakthrough for hair loss.
- Shares of ABSI jumped about 18% on heavy volume after Leerink’s initiation, a sharp move from roughly $7 that highlights growing momentum trading.
- Absci will be featured at Jones AI Day as a leading generative‑biology player, adding AI‑themed visibility while at least one AI-designed antibody advances through Phase 1 trials.
Live Update At 09:18:58 EDT: On Wednesday, June 24, 2026 Absci Corporation stock [NASDAQ: ABSI] is trending up by 28.2%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
ABSI is a classic high-risk, high-upside biotech story. The numbers show why traders treat it like a momentum vehicle, not a value play. Absci generated only about $2.8M in revenue over the last year, yet carries a price‑to‑sales ratio above 400. That means traders are paying up for future potential, not current cash flow.
Margins tell the same story. Absci’s profit margin and EBIT margin are deeply negative, reflecting heavy research and development spending. In the latest quarter, ABSI booked just $215,000 in revenue versus more than $31M in operating expenses, driving a net loss of about $29.6M and free cash flow of roughly -$26.3M. This is burn, not earnings.
More Breaking News
- KEEL Stock Grinds Higher As Traders Focus On Cash And Volatility
- BOLD Stock Grinds Sideways As Traders Eye Cash Runway
- APGE Stock Climbs As Zumilokibart Data And Blackstone Deal Reprice The Story
- CHTR Stock Steadies As Spectrum Reach Leans Into AI Ads
The balance sheet, though, gives ABSI time. With roughly $125.7M in cash and short‑term investments, a current ratio of 6.6, and minimal debt, Absci has runway to push ABS-201 and its AI pipeline forward. On the chart, ABSI has run from around $6.40 to the mid‑$7s over the past couple of weeks, with sharp spikes like the 18% Leerink‑driven pop. For traders, this mix of strong cash, steep losses, and volatile price action screams “catalyst stock” tied to data and headlines.
Why Traders Are Watching Absci Now
Traders are zeroed in on Absci because Wall Street has essentially planted a big neon sign over ABSI. First came Leerink, initiating coverage with an Outperform rating and a $12 target, well above the recent ~$7–$8 trading range. That call leaned heavily on Absci’s AI‑native drug discovery engine and its lead asset, ABS-201, now in Phase 1/2 for androgenetic alopecia and moving toward Phase 2 in endometriosis.
The market didn’t ignore it. ABSI ripped roughly 18% on heavy volume after the Leerink note hit, a clear sign that new money is piling into the story. For short‑term traders, that kind of volume‑backed spike often marks the start of a momentum phase, not the end — as long as the news flow keeps feeding the fire.
Then Guggenheim raised the stakes, lifting its Absci target to $15 from $10 and reiterating a Buy. The firm now models more than $5B in U.S. sales and over $8B globally for ABS-201 if the data cooperate, with key proof‑of‑concept readouts due in the second half of the year. BTIG added fuel with a Buy rating, a $9 target, and a $2.2B peak‑sales view, even likening ABS-201’s potential in hair loss to GLP‑1’s impact in obesity.
Layer on top the AI narrative. Absci is being positioned as a leading generative‑biology shop, using AI plus a wet lab to design antibodies from scratch, with at least one AI‑designed molecule already in Phase 1. ABSI’s appearance on a Jones AI Day panel, alongside other compute and biology players, reinforces that brand. None of that adds revenue today, but it keeps ABSI squarely in the crosshairs of traders chasing AI‑plus‑biotech themes.
Conclusion
For active traders, ABSI is now a pure catalyst and sentiment play wrapped around ABS-201 and Absci’s AI story. The hard data are clear: the business is still tiny in revenue terms, bleeding cash, and nowhere near profitability. But the Street is starting to model massive upside if ABS-201 works, with price targets ranging from $9 to $15 and peak‑sales scenarios stretching from $2.2B to more than $8B.
That kind of gap between current fundamentals and future projections is exactly where momentum trading thrives — and where risk cuts both ways. Positive Phase 1/2 or proof‑of‑concept data on ABS-201, especially in the second half of the year, could keep re‑rating ABSI higher. Disappointing or even “just okay” data can do the opposite and unwind the recent 18% rally and more. Routine insider Form 4 activity in ABSI has been reported, but without clear direction in the public summary, the real driver remains clinical and analyst news.
Absci’s positioning at the intersection of generative AI and drug discovery, plus its role on the Jones AI Day panel, helps sustain long‑term buzz. Still, traders need to remember what Tim Sykes pounds into his students: “Trade the catalyst, not the hype, and always, always cut losses quickly.” That mindset lines up with his broader message about process and discipline; as millionaire penny stock trader and teacher Tim Sykes, says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.”. For ABSI, that means respecting both the big upside sketched by Guggenheim, Leerink, and BTIG — and the equally real downside if the science fails to match the story.
This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.
Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:
- Penny Stocks Trading Guide
- Best Penny Stocks Under $1 to Buy Today
- Top 8 Penny Stocks to Watch on Robinhood
Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:
Leave a reply